Drugs / Four Factor Prothrombin Complex Concentrate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT03473132 | Mar 2018 → Dec 2021 | — | Brigham and Women's Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02429453 | Apr 2015 → Mar 2016 | brain injury, intracerebral hemorrhage | University of Utah | Withdrawn | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-04-07 | Octapharma | Study suggests that 4F-PCC can be used as a substitute for frozen plasma for the treatment of bleeding during cardiac surgery octapharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Four Factor Prothrombin Complex Concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02429453 ↗ |
| Known as | 4F-PCC | “Four-factor prothrombin complex concentrate (4F-PCC) can temporarily restore hemostasis in patients undergoing anticoagulation with warfarin.” PMID 38521486 ↗ Mar 2024 |
| Action | Restore | “method for correcting vitamin K antagonist related coagulopathy” NCT02429453 ↗ |
| Modality | Protein / enzyme biologic | “A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S” NCT02429453 ↗ |